Psychobiologic effects of 3,4-methylenedioxymethamphetamine in humans: methodological considerations and preliminary observations

Behavioural Brain Research

Volumn 73, Issue 1-2, 1995, Pages 103-107

  Grob, Charles S ^a   Poland, Russell E ^a   Chang, Linda ^a   Ernst, Thomas ^a  

^a HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

3,4 Methylenedioxymethamphetamine (MDMA); Fenfluramine; Hallucinogen; Neuroendocrine challenge; Neurotoxicity; Serotonin; Single photon emission computerized tomography (SPECT); Spectroscopy

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; CORTICOTROPIN;

CONFERENCE PAPER; CONTROLLED STUDY; HALLUCINATION; HUMAN; HUMAN EXPERIMENT; NEUROPSYCHOLOGICAL TEST; NEUROTOXICITY; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ADULT; BLOOD PRESSURE; BODY TEMPERATURE; CENTRAL NERVOUS SYSTEM; CEREBROVASCULAR CIRCULATION; DOUBLE-BLIND METHOD; FEMALE; HALLUCINOGENS; HEART RATE; HORMONES; HUMANS; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; PROSPECTIVE STUDIES; SEROTONIN; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 13344260012     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/0166-4328(96)00078-2     Document Type: Article

References (32)

1. Persistent effects of MDMA (Ecstasy) on human sleep
2. Increasing use of ‘Ecstasy’ (MDMA) and other hallucinogens on a college campus
3. Absolute quantitation of water and metabolites in the human brain. I. Compartments and water
4. Localized proton spectroscopy using stimulated echoes
5. The therapeutic use of MDMA
6. Can drugs be used to enhance the psychotherapeutic process?
7. Second thoughts on 3,4-methylenedioxy-methamphetamine (MDMA) neurotoxicity
8. The MDMA-neurotoxicity controversy: implications for clinical research with novel psychoactive drugs
9. Toxicity and deaths from 3,4-methylenedioxymethamphetamine
10. Absolute quantitation of water and metabolites in the human brain. II. Metabolite concentrations
11. Chronic MDMA use: effects on mood and neuropsychological function
12. Schedules of controlled substances: scheduling of 3,4-methylenedioxymethamphetamine (MDMA) into Schedule I
13. Phenomenology and sequelae of 3,4-methylenedioxymethamphetamine use
14. Serotonin neurotoxicity after 3,4-methylenedioxymethamphetamine (MDMA): A controlled study in humans
15. Diversity of psychophathology associated with use of 3,4-methylenedioxymethamphetamine (‘Ecstasy’)
16. Neurochemistry and neurotoxicity of 3,4-methylenedioxymethamphetamine
17. Elevation of serum prolactin and corticosterone concentrations in the rat after the administration of 3,4-methlenedioxymethamphetamine
18. Incidence of recreational use of 3,4-methylenedioxymethamphetamine (MDMA) on an undergraduate campus
19. Neuroendocrine and mood responses to intravenous L-tryptophan in 3,4-methylenedioxymethamphetamine (MDMA) users
20. Hallucinogenic amphetamine selectively destroys brain serotonin nerve terminals
21. Clinical tools for the 90s: magnetic resonance spectroscopy and metabolite imaging
22. Characterization of three new psychotomimetics
23. Dose-response study of N,N-Dimethyltryptamine in humans II. Subjective effects and preliminary results of a new rating scale
24. Neuroendocrine pharmacology of 5-HT neurons
25. New age seekers: MDMA use in spiritual pursuit
26. Opinion and recommended ruling findings of fact conclusions of law and decision of administrative law judge Submitted in the matter of MDMA scheduling